DOCSLIB.ORG

Type I IFN Receptor-Signaling Complex Functions As a Scaffold

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Type I IFN Receptor-Signaling Complex Functions As a Scaffold The WD Motif-Containing Protein RACK-1 Functions as a Scaffold Protein Within the Type I IFN Receptor-Signaling Complex This information is current as Anna Usacheva, Xinyong Tian, Raudel Sandoval, Debra of September 28, 2021. Salvi, David Levy and Oscar R. Colamonici J Immunol 2003; 171:2989-2994; ; doi: 10.4049/jimmunol.171.6.2989 http://www.jimmunol.org/content/171/6/2989 Downloaded from References This article cites 39 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/171/6/2989.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The WD Motif-Containing Protein RACK-1 Functions as a Scaffold Protein Within the Type I IFN Receptor-Signaling Complex1 Anna Usacheva,2* Xinyong Tian,2* Raudel Sandoval,* Debra Salvi,* David Levy,† and Oscar R. Colamonici3* The WD repeat-containing protein receptor for activated protein kinase C (RACK)-1 has been linked to a variety of signaling systems including protein kinase C, growth factors, and IFNs. In the IFN system, RACK-1 functions as an adaptor recruiting the transcription factor STAT1 to the receptor complex. However, RACK-1 should play a broader role in type I IFN signaling because mutation of the RACK-1 binding site in the IFN-␣ receptor 2/␤ subunit of the type I IFN receptor abrogates not only STAT1, but also STAT2, activation. In this study, we demonstrate that RACK-1 serves as a scaffold protein for a multiprotein complex that Downloaded from includes the IFN-␣ receptor 2/␤-chain of the receptor, STAT1, Janus kinase 1, and tyrosine kinase 2. In vitro data further suggest that within this complex tyrosine kinase 2 is the tyrosine kinase responsible for the phosphorylation of STAT1. Finally, we provide evidence that RACK-1 may also serve as a scaffold protein in other cytokine systems such as IL-2, IL-4, and erythropoietin. The Journal of Immunology, 2003, 171: 2989–2994. ytokines and IFNs (1–3) activate kinases of the Janus to the receptor complex and no specific STAT1-docking tyrosine http://www.jimmunol.org/ kinase (Jak)4 family and transcription factors designated has been identified within the ␣ or ␤ subunits of the receptor (13, C as STAT (4–7). Although there is some promiscuity in 15, 20, 21). Moreover, the tyrosine phosphorylation of STAT1 STAT activation by different cytokines (i.e., STAT1 is activated requires the previous phosphorylation of STAT2 (22). Interest- by IFN-␣, IFN-␥, IL-6, LIF, IL-10, etc.), specific knockout mice ingly, mutation of the RACK-1 binding site of ␤L has an impact models have demonstrated that the biological role of a distinct on type I IFN signaling that goes beyond activation of STAT1 STAT is restricted to specific systems (for review see Ref. 8). For because it also impairs activation/phosphorylation of STAT2. This example, STAT1 is only specifically required for type I (IFN-␣, finding raises the question as to whether RACK-1 recruits other -␤,or-␻) and type II (IFN-␥) signaling (9, 10). signaling components to the receptor complex. In most cytokine systems, activation of STATs through tyrosine RACK-1 functions are not restricted to protein kinase C (PKC) by guest on September 28, 2021 phosphorylation requires their previous recruitment to distinct or IFN signaling because RACK-1 interacts with Src homology 2 phosphotyrosines within the receptor subunits (reviewed in Refs. (SH2)-containing proteins such as src, phospholipase C ␥, and ras- 7, 8, and 11). In the case of the type I IFNR, STAT2 is constitu- GTPase-activating protein (GAP) (23, 24), ␤ integrins (25), tively associated with the ␤L subunit (also designated as IFN-␣ PDE4D5 (26), the ␤ common subunit of the GM-CSF/IL-3/IL-5 receptor 2) in a phosphotyrosine-independent manner and has ad- receptors (27), and insulin-like growth factor (IGF) receptor (28). ditional phosphotyrosine-dependent docking sites on the ␣ and ␤L Because RACK-1 is a WD repeat-contained protein with no en- chain (12–16). Interestingly, full activation of STAT2 by type I zymatic activity it has been proposed that it functions as a scaffold IFNs requires the presence of at least two of these three docking protein that recruits specific signaling elements. For instance, scaf- sites (13). Activation of STAT1 by type I IFNs differs significantly fold proteins bring together multiple components of the mitogen- from its activation by IFN-␥ and the activation of STATs in gen- activated protein kinase signaling (29, 30). eral by other cytokines. For example, the adaptor protein receptor We sought to determine whether RACK-1, in addition to serving for activated protein kinase C (RACK)-1 (17–19) recruits STAT1 as an adaptor between the ␤L chain of the receptor and STAT1, was required for docking other components of the type I IFN re- ceptor system such as Jak1 and tyrosine kinase (Tyk)2. We also *Department of Pharmacology, University of Illinois, Chicago, IL 60612; and †De- endeavored to determine whether Jak1 and Tyk2 could be respon- partment of Pathology, New York University School of Medicine, New York, New sible for tyrosine phosphorylation of STAT1 and STAT2. Our York 10016 findings indicate that RACK-1 directly interacts with Tyk2 and Received for publication April 14, 2003. Accepted for publication July 16, 2003. Jak1, however, only Tyk2 can phosphorylate STAT1 in vitro. Fi- The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance nally, we provide evidence that RACK-1 associates with other with 18 U.S.C. Section 1734 solely to indicate this fact. cytokine receptors such as erythropoietin, IL-2R␤, and IL-4R␣, 1 This work was supported by National Institutes of Health Grants CA55079 and suggesting that RACK-1 could play a role in signaling by other GM54709 (to O.R.C.). cytokines. 2 A.U. and X.T. contributed equally to this manuscript. 3 Address correspondence and reprint requests to Dr. Oscar R. Colamonici, Depart- Materials and Methods ment of Pharmacology (M/C868), University of Illinois, 835 South Wolcott Avenue, Cell lines, reagents, and antiviral assays Room E403, Chicago, IL 60612. E-mail address: [email protected]. 4 Abbreviations used in this paper: Jak, Janus kinase; RACK, receptor for activated U-266 and L-929 cells were grown in RPMI 1640 supplemented with 10% 8 protein kinase C; SH2, Src homology 2; IGF, insulin-like growth factor; Tyk, tyrosine (v/v) FBS. Human IFN-␣2 (specific activity 2.2 ϫ 10 U/mg) was a gift of kinase; PKC, protein kinase C; EPOR, erythropoietin receptor. R. Bordens (Schering-Plough, Kenilworth, NJ). The anti-phosphotyrosine Copyright © 2003 by The American Association of Immunologists, Inc. 0022-1767/03/$02.00 2990 RACK-1 AND IFN SIGNALING Ab 4G10 was purchased from Upstate Biotechnology (Lake Placid, NY) and the anti-RACK-1 (IgM), -STAT1, and -Jak1 mAbs were purchased from BD Transduction Laboratories (Lexington, KY). The anti-RACK1 Ab (IgG) used for the experiments described (see Fig. 2C) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-STAT1 sera were kindly provided by Dr. A. Larner (Cleveland Clinic, Cleveland, OH). Immunoprecipitation and immunoblotting Cells (1 ϫ 107 cells/immunoprecipitation) were treated as indicated, and then lysed in lysis buffer (20 mM Tris-HCl, pH 6.6, containing 1% Nonidet P-40, 50 mM NaCl, 1 mM EDTA, 2.5% glycerol v/v, 1.0 mM sodium fluoride, 1.0 mM sodium orthovanadate, 1.0 mM PMSF, 0.5 ␮g/ml leu- peptin, and 5.0 ␮g/ml trypsin inhibitor) for 30 min at 4°C. Immunopre- cipitations were performed as previously described (13). Proteins were transferred to polyvinylidene difluoride membranes, immunoblotted with the indicated Abs, and developed using a chemiluminescent detection method (Pierce, Rockford, IL). GST-fusion proteins and mammalian expression construct The different GST fusion proteins encoding the cytoplasmic domain of the ␣ and ␤L subunits of the type I IFNR, IL-2R␤, IL-4␣, and GST-RACK-1 have been described previously (31, 32). GST-STAT1 corresponds to the Downloaded from full-length STAT1 sequence subcloned into pGEX-2T. For in vitro kinase assays, GST-STAT1 was eluted from the GSH-Sepharose beads using 10 mM glutathione and ϳ2–4 ␮g/assay used as substrate. The amount of GST used per pull-down was estimated from gels stained with Coomassie blue FIGURE 1. RACK-1 interacts with tyrosine-phosphorylated proteins. and compared to BSA standards. Pull-down experiments and immunoblot- U-266 (2 ϫ 107 cells/immunoprecipitation) lysates obtained from IFN-␣- ting were performed using the same procedure described above for treated (10,000 U/ml) or control cells were used for pull-down experiments immunoprecipitations. with the indicated GST fusion proteins or for immunoprecipitation with a http://www.jimmunol.org/ In vitro translation and in vitro kinase assays combination of anti-STAT1 and anti-STAT2 Abs.
Load more

Recommended publications
  • Erb‑B2 Receptor Tyrosine Kinase 2 Is Negatively Regulated by the P53‑Responsive Microrna‑3184‑5P in Cervical Cancer Cells
    ONCOLOGY REPORTS 45: 95-106, 2021 Erb‑B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53‑responsive microRNA‑3184‑5p in cervical cancer cells HONGLI LIU1, YUZHI LI1, JING ZHANG1, NAN WU2, FEI LIU2, LIHUA WANG1, YUAN ZHANG1, JING LIU1, XUAN ZHANG3, SUYANG GUO1 and HONGTAO WANG4 Departments of 1Gynecological Oncology and 2Respiration and Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, First Affiliated Hospital of Bengbu Medical College; Departments of3 Gynecological Oncology and 4Immunology and Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China Received November 30, 2019; Accepted October 2, 2020 DOI: 10.3892/or.2020.7862 Abstract. The oncogenic role of Erb-B2 Receptor Tyrosine Introduction Kinase 2 (ERBB2) has been identified in several types of cancer, but less is known on its function and mechanism of Among women, cervical cancer is ranked 4th in global action in cervical cancer cells. The present study employed cancer-associated deaths (1), with over half a million deaths a multipronged approach to investigate the role of ERBB2 in in 2012 (2). Cervical cancer can be broadly categorized into cervical cancer. ERBB2 and microRNA (miR)-3184-5p expres- squamous cell carcinoma, which constitutes the majority of sion was assessed in patient-derived cervical cancer biopsy cases (70-80%) or adenocarcinoma, which comprises 10-15% tissues, revealing that higher levels of ERBB2 and lower levels of cases (3). Cervical cancer is frequently caused by the of miR-3184-5p were associated with clinicopathological indi- oncovirus human papillomavirus (HPV), mainly by types cators of cervical cancer progression.
    [Show full text]
  • The Wnt Pathway Scaffold Protein Axin Promotes Signaling Specificity by Suppressing Competing Kinase Reactions
    bioRxiv preprint doi: https://doi.org/10.1101/768242; this version posted September 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The Wnt pathway scaffold protein Axin promotes signaling specificity by suppressing competing kinase reactions Maire Gavagan1,2, Erin Fagnan1,2, Elizabeth B. Speltz1, and Jesse G. Zalatan1,* 1Department of Chemistry, University of Washington, Seattle, WA 98195, USA 2These authors contributed equally to this work *Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/768242; this version posted September 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract GSK3β is a multifunctional kinase that phosphorylates β-catenin in the Wnt signaling network and also acts on other protein targets in response to distinct cellular signals. To test the long-standing hypothesis that the scaffold protein Axin specifically accelerates β-catenin phosphorylation, we measured GSK3β reaction rates with multiple substrates in a minimal, biochemically-reconstituted system. We observed an unexpectedly small, ~2-fold Axin-mediated rate increase for the β-catenin reaction. The much larger effects reported previously may have arisen because Axin can rescue GSK3β from an inactive state that occurs only under highly specific conditions.
    [Show full text]
  • CK1 Is Required for a Mitotic Checkpoint That Delays Cytokinesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Current Biology 23, 1920–1926, October 7, 2013 ª2013 Elsevier Ltd All rights reserved http://dx.doi.org/10.1016/j.cub.2013.07.077 Report CK1 Is Required for a Mitotic Checkpoint that Delays Cytokinesis Alyssa E. Johnson,1 Jun-Song Chen,1 isoforms were detected, which collapsed into a discrete ladder and Kathleen L. Gould1,* upon phosphatase treatment (Figure 1A, lanes 1 and 2). These 1Department of Cell and Developmental Biology, Vanderbilt bands are ubiquitinated isoforms because they collapse into a University School of Medicine, Nashville, TN 37232, USA single band in the absence of dma1+ (Figure 1A, lane 4) and Dma1 is required for Sid4 ubiquitination [6]. In dma1D cells, a single slower-migrating form of Sid4 was detected, which Summary was collapsed by phosphatase treatment, indicating that Sid4 is phosphorylated in vivo (Figure 1A, lanes 3 and 4). In vivo Failure to accurately partition genetic material during cell radiolabeling experiments validated Sid4 as a phosphoprotein division causes aneuploidy and drives tumorigenesis [1]. and revealed that Sid4 is phosphorylated on serines and thre- Cell-cycle checkpoints safeguard cells from such catastro- onines (see Figures S1A–S1C available online). The constitu- phes by impeding cell-cycle progression when mistakes tive presence of an unmodified Sid4 isoform indicates that arise. FHA-RING E3 ligases, including human RNF8 [2] and only a subpopulation of Sid4 is modified (Figure 1A). Collec- CHFR [3] and fission yeast Dma1 [4], relay checkpoint signals tively, these data indicate that Sid4 is ubiquitinated and phos- by binding phosphorylated proteins via their FHA domains phorylated in vivo.
    [Show full text]
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Supplementary Materials
    Supplementary Suppl. Figure 1: MAPK signalling pathway of A: NCI-H2502, B: NCI-H2452, C: MSTO-211H and D: MRC-5. Suppl. Figure 2: Cell cycle pathway of A: NCI-H2502, B: NCI-H2452, C: MSTO-211H and D: MRC- 5. Suppl. Figure 3: Cancer pathways of A: NCI-H2502, B: NCI-H2452, C: MSTO-211H and D: MRC-5. Suppl. Figure 4: Phosphorylation level of A: ARAF, B: EPHA1, C: EPHA2, D: EPHA7 in all cell lines. For each cell line, phosphorylation levels are depicted before (Medium) and after cisplatin treatment (Cis). Suppl. Figure 5: Phosphorylation Level of A: KIT, B: PTPN11, C: PIK3R1, D: PTPN6 in all cell lines. For each cell line, phosphorylation levels are depicted before (Medium) and after cisplatin treatment (Cis). Suppl. Figure 6: Phosphorylation Level of A: KDR, B: EFS, C: AKT1, D: PTK2B/FAK2 in all cell lines. For each cell line, phosphorylation levels are depicted before (Medium) and after cisplatin treatment (Cis). Suppl. Figure 7: Scoreplots and volcanoplots of PTK upstream kinase analysis: A: Scoreplot of PTK- Upstream kinase analysis for NCI-H2052 cells. B: Volcanoplot of PTK-Upstream kinase analysis for NCI-H2052 cells. C: Scoreplot of PTK-Upstream kinase analysis for NCI-H2452 cells. D: Volcanoplot of PTK-Upstream kinase analysis for NCI-H2452 cells. E: Scoreplot of PTK-Upstream kinase analysis for MSTO-211H cells. F: Volcanoplot of PTK-Upstream kinase analysis for MSTO- 211H cells. G: Scoreplot of PTK-Upstream kinase analysis for MRC-5cells. H: Volcanoplot of PTK- Upstream kinase analysis for MRC-5 cells. Suppl. Figure 8: Scoreplots and volcanoplots of STK upstream kinase analysis: A: Scoreplot of STK- Upstream kinase analysis for NCI-H2052 cells.
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • Impact of Digestive Inflammatory Environment and Genipin
    International Journal of Molecular Sciences Article Impact of Digestive Inflammatory Environment and Genipin Crosslinking on Immunomodulatory Capacity of Injectable Musculoskeletal Tissue Scaffold Colin Shortridge 1, Ehsan Akbari Fakhrabadi 2 , Leah M. Wuescher 3 , Randall G. Worth 3, Matthew W. Liberatore 2 and Eda Yildirim-Ayan 1,4,* 1 Department of Bioengineering, College of Engineering, University of Toledo, Toledo, OH 43606, USA; [email protected] 2 Department of Chemical Engineering, College of Engineering, University of Toledo, Toledo, OH 43606, USA; [email protected] (E.A.F.); [email protected] (M.W.L.) 3 Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USA; [email protected] (L.M.W.); [email protected] (R.G.W.) 4 Department of Orthopaedic Surgery, University of Toledo Medical Center, Toledo, OH 43614, USA * Correspondence: [email protected]; Tel.: +1-419-530-8257; Fax: +1-419-530-8030 Abstract: The paracrine and autocrine processes of the host response play an integral role in the success of scaffold-based tissue regeneration. Recently, the immunomodulatory scaffolds have received huge attention for modulating inflammation around the host tissue through releasing anti- inflammatory cytokine. However, controlling the inflammation and providing a sustained release of anti-inflammatory cytokine from the scaffold in the digestive inflammatory environment are predicated upon a comprehensive understanding of three fundamental questions. (1) How does the Citation: Shortridge, C.; Akbari release rate of cytokine from the scaffold change in the digestive inflammatory environment? (2) Fakhrabadi, E.; Wuescher, L.M.; Can we prevent the premature scaffold degradation and burst release of the loaded cytokine in the Worth, R.G.; Liberatore, M.W.; digestive inflammatory environment? (3) How does the scaffold degradation prevention technique Yildirim-Ayan, E.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Crosstalk Between Casein Kinase II and Ste20-Related Kinase Nak1
    University of Massachusetts Medical School eScholarship@UMMS GSBS Student Publications Graduate School of Biomedical Sciences 2013-03-05 Crosstalk between casein kinase II and Ste20-related kinase Nak1 Lubos Cipak University of Vienna Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_sp Part of the Biochemistry Commons, Cell Biology Commons, Cellular and Molecular Physiology Commons, and the Molecular Biology Commons Repository Citation Cipak L, Gupta S, Rajovic I, Jin Q, Anrather D, Ammerer G, McCollum D, Gregan J. (2013). Crosstalk between casein kinase II and Ste20-related kinase Nak1. GSBS Student Publications. https://doi.org/ 10.4161/cc.24095. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/1850 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Student Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. EXTRA VIEW Cell Cycle 12:6, 884–888; March 15, 2013; © 2013 Landes Bioscience Crosstalk between casein kinase II and Ste20-related kinase Nak1 Lubos Cipak,1,2,† Sneha Gupta,3,† Iva Rajovic,1 Quan-Wen Jin,3,4 Dorothea Anrather,1 Gustav Ammerer,1 Dannel McCollum3,* and Juraj Gregan1,5,* 1Max F. Perutz Laboratories; Department of Chromosome Biology; University of Vienna; Vienna, Austria; 2Cancer Research Institute; Slovak Academy of Sciences; Bratislava, Slovak Republic; 3Department of Microbiology and Physiological Systems and Program in Cell Dynamics; University of Massachusetts Medical School; Worcester, MA USA; 4Department of Biological Medicine; School of Life Sciences; Xiamen University; Xiamen, China; 5Department of Genetics; Comenius University; Bratislava, Slovak Republic †These authors contributed equally to this work.
    [Show full text]
  • Electrical Synaptic Transmission Requires a Postsynaptic Scaffolding Protein
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.03.410696; this version posted December 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. TITLE: Electrical synaptic transmission requires a postsynaptic scaffolding protein Abagael M. Lasseigne1*, Fabio A. Echeverry2*, Sundas Ijaz2*, Jennifer Carlisle Michel1*, E. Anne Martin1, Audrey J. Marsh1, Elisa Trujillo1, Kurt C. Marsden3, Alberto E. Pereda2#, Adam C. Miller1#@ * denotes co-first author # denotes co-corresponding author @ denotes lead contact Affiliations: 1 Institute of Neuroscience, University of Oregon, Eugene, OR 97403, USA 2 Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA 3 Department of Biological Sciences, NC State University, Raleigh, NC 27695, USA Correspondence: [email protected] [email protected] Keywords: gap junction; connexin; ZO1 ZO-1; synaptic development; electrical coupling 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.03.410696; this version posted December 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. SUMMARY Electrical synaptic transmission relies on neuronal gap junctions containing channels constructed by Connexins. While at chemical synapses neurotransmitter-gated ion channels are critically supported by scaffolding proteins, it is unknown if channels at electrical synapses require similar scaffold support.
    [Show full text]